Endometrial Cancer - Global Clinical Trial Landscape (2024)

Explore cutting-edge endometrial cancer research with Novotech CRO's disease report, covering new treatments, clinical trials, and future innovations in care.

Endometrial cancer, a leading cause of gynaecological cancer deaths, primarily affects postmenopausal women. Risk factors include extended estrogen exposure, obesity, hypertension, diabetes, and genetic syndromes. Projections suggest new uterine cancer cases may surpass 600,000 annually by 2044.

Management involves surgery, systemic therapy, and radiotherapy, guided by tumor histopathology and patient factors. Recent FDA approvals, like dostarlimab-gxly and pembrolizumab with lenvatinib, expand treatment options. Global efforts, including ESMO guideline adaptations, aim to optimize care.

Endometrial cancer's global burden includes 420,370 new cases and 97,720 deaths in 2022. Asia records the highest incidence, followed by Europe and North America. Since 2018, over 1200 trials have been initiated, with North America and Asia-Pacific leading.

Novotech, with over 25 years of experience and hundreds of oncology trials, offers tailored CRO services to enhance endometrial cancer research. Download our comprehensive disease report to learn more.